Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia (NCT00818610) | Clinical Trial Compass
CompletedPhase 4
Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia
Switzerland601 participantsStarted 2009-01
Plain-language summary
The purpose of this study is to determine whether a monotherapy with a Beta-Lactam is not inferior to an association of a Beta-Lactam and a macrolide in treating adult patients with community-acquired pneumonia.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age \>=18 years
* New infiltrate on chest X-ray, unexplained by another disease process
* Presence of at least two of the following findings suggestive of pneumonia: fever or hypothermia, new or increasing cough, sputum production, pleuritic chest pain, tachypnea, dyspnea or focal signs on chest examination
* Need for hospitalization as defined by the emergency physician in charge of the patient
Exclusion Criteria:
* Allergy to one of the study drugs
* Pregnancy
* Severe immunosuppression
* Recent (\<14 d) hospitalization, or currently hospitalized since \> 48 hours
* Residency in a nursing home
* Previous use of more than 24 hours of any antibiotic
* Severe community-acquired pneumonia
What they're measuring
1
Time to Clinical Stability (hours)
Timeframe: 30 days
Trial details
NCT IDNCT00818610
SponsorSwiss National Fund for Scientific Research